25 May 2018 - Indivior today announced that it has filed a regulatory submission with Australia’s TGA for Sublocade (buprenorphine extended-release) injection, for subcutaneous use, for the treatment of opioid dependence within a framework of medical, social and psychological treatment. 

If approved, Sublocade will be marketed by Indivior in Australia.

The TGA submission follows the approval of Sublocade by the U.S. FDA on 30 November 2017 and the new drug submission to Health Canada on 20 April 2018.

Read Indivior press release